Highlander Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $1.7M | Buy |
61,324
+23,655
| +63% | +$656K | 0.58% | 38 |
|
|
2023
Q4 | $1.08M | Buy |
37,669
+12,700
| +51% | +$384K | 0.39% | 62 |
|
|
2023
Q3 | $828K | Buy |
24,969
+8,566
| +52% | +$303K | 0.33% | 72 |
|
|
2023
Q2 | $602K | Sell |
16,403
-300
| -2% | -$11.7K | 0.28% | 75 |
|
|
2023
Q1 | $681K | Hold |
16,703
| – | – | 0.33% | 70 |
|
|
2022
Q4 | $856K | Hold |
16,703
| – | – | 0.45% | 53 |
|
|
2022
Q3 | $731K | Sell |
16,703
-550
| -3% | -$26.7K | 0.42% | 60 |
|
|
2022
Q2 | $905K | Buy |
17,253
+150
| +0.9% | +$7.64K | 0.49% | 55 |
|
|
2022
Q1 | $885K | Sell |
17,103
-600
| -3% | -$31.1K | 0.41% | 59 |
|
|
2021
Q4 | $1.04M | Sell |
17,703
-50
| -0.3% | -$2.48K | 0.48% | 52 |
|
|
2021
Q3 | $764K | Hold |
17,753
| – | – | 0.39% | 61 |
|
|
2021
Q2 | $695K | Hold |
17,753
| – | – | 0.35% | 72 |
|
|
2021
Q1 | $643K | Sell |
17,753
-5,850
| -25% | -$208K | 0.34% | 72 |
|
|
2020
Q4 | $869K | Sell |
23,603
-7,599
| -24% | -$279K | 0.49% | 49 |
|
|
2020
Q3 | $1.09M | Sell |
31,202
-52
| -0.2% | -$1.82K | 0.66% | 38 |
|
|
2020
Q2 | $970K | Buy |
31,254
+13,965
| +81% | +$474K | 0.61% | 41 |
|
|
2020
Q1 | $535K | Buy |
17,289
+106
| +0.6% | +$3.61K | 0.38% | 63 |
|
|
2019
Q4 | $639K | Sell |
17,183
-527
| -3% | -$18.8K | 0.37% | 70 |
|
|
2019
Q3 | $604K | Sell |
17,710
-1,265
| -7% | -$46K | 0.37% | 71 |
|
|
2019
Q2 | $780K | Hold |
18,975
| – | – | 0.47% | 60 |
|
|
2019
Q1 | $765K | Sell |
18,975
-422
| -2% | -$16.9K | 0.47% | 57 |
|
|
2018
Q4 | $799K | Hold |
19,397
| – | – | 0.53% | 49 |
|
|
2018
Q3 | $811K | Sell |
19,397
-263
| -1% | -$10.1K | 0.45% | 63 |
|
|
2018
Q2 | $677K | Hold |
19,660
| – | – | 0.38% | 75 |
|
|
2018
Q1 | $648K | Buy |
19,660
+4,622
| +31% | +$159K | 0.39% | 73 |
|
|
2017
Q4 | $517K | Sell |
15,038
-211
| -1% | -$7.2K | 0.38% | 72 |
|
|
2017
Q3 | $517K | Sell |
15,249
-211
| -1% | -$6.78K | 0.4% | 72 |
|
|
2017
Q2 | $496K | Buy |
15,460
+3,188
| +26% | +$101K | 0.39% | 68 |
|
|
2017
Q1 | $398K | Hold |
12,272
| – | – | 0.33% | 84 |
|
|
2016
Q4 | $378K | Buy |
12,272
+1,265
| +11% | +$38.6K | 0.33% | 83 |
|
|
2016
Q3 | $354K | Hold |
11,007
| – | – | 0.32% | 90 |
|
|
2016
Q2 | $368K | Hold |
11,007
| – | – | 0.34% | 81 |
|
|
2016
Q1 | $310K | Sell |
11,007
-335
| -3% | -$9.57K | 0.29% | 98 |
|
|
2015
Q4 | $348K | Sell |
11,342
-2,109
| -16% | -$66.3K | 0.32% | 84 |
|
|
2015
Q3 | $400K | Buy |
13,451
+1
| +0% | +$32 | 0.38% | 67 |
|
|
2015
Q2 | $428K | Sell |
13,450
-2,710
| -17% | -$88.3K | 0.38% | 70 |
|
|
2015
Q1 | $533K | Buy |
16,160
+1,582
| +11% | +$50.3K | 0.46% | 53 |
|
|
2014
Q4 | $431K | Buy |
14,578
+2
| +0% | +$57 | 0.37% | 71 |
|
|
2014
Q3 | $409K | Buy |
14,576
+1
| +0% | +$28 | 0.39% | 69 |
|
|
2014
Q2 | $410K | Buy |
14,575
+1
| +0% | +$29 | 0.37% | 74 |
|
|
2014
Q1 | $444K | Buy |
14,574
+1
| +0% | +$30 | 0.42% | 61 |
|
|
2013
Q4 | $424K | Buy |
14,573
+1
| +0% | +$29 | 0.4% | 67 |
|
|
2013
Q3 | $397K | Buy |
14,572
+2
| +0% | +$54 | 0.4% | 66 |
|
|
2013
Q2 | $387K | Buy |
+14,570
| New | +$403K | 0.41% | 64 |
|
Other funds holding PFE
Highlander Capital Management's PFE Position: Q1 2024 in Review
Highlander Capital Management increased its Pfizer (PFE) stake by 63% in Q1 2024, buying an estimated $656K and bringing the position to 61,324 shares worth $1.7M. The position accounts for 0.58% of the portfolio, ranked #38.
Highlander Capital Management first reported a position in PFE in Q2 2013 and has held it in 44 quarters since. 2,875 funds tracked by Wall St. Rank hold PFE as of Q1 2024.
- Highlander Capital Management held 61,324 shares of Pfizer worth $1.7M as of Q1 2024.
- Highlander Capital Management bought 23,655 Pfizer shares in Q1 2024, an estimated $656K.
- Pfizer made up 0.58% of Highlander Capital Management's portfolio in Q1 2024, its #38 holding.
- Highlander Capital Management first reported a position in Pfizer in Q2 2013 and has held it in 44 quarters since.
- 2,875 funds tracked by Wall St. Rank held Pfizer as of Q1 2024.
Based on Highlander Capital Management's 13F filing for Q1 2024, filed 20 May 2024.